In spite of successful studies as part of gene-based analysis, they could not capture the whole picture of resistance mechanisms to targeted therapies in HER2+ breast cancer patients due to the complexity of HER2+ tumor biology (Nahta, 2012; de Melo Gagliato et al., 2016; Zhang et al., 2017). This evidence concerns the gene ERBB2 and neoplasm.